Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The KEY to the end of the chemotherapy in advanced non-small cell lung cancer, or not yet?

Huang Y, Walsh RJ, Soo RA.

Transl Lung Cancer Res. 2019 Oct;8(5):731-737. doi: 10.21037/tlcr.2019.04.17. No abstract available.

2.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.

J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640-8. doi: 10.1016/j.jtho.2019.10.022. [Epub ahead of print] Review.

PMID:
31733357
3.

Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.

Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI.

Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25.

PMID:
31669155
4.

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer.

Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC.

EMBO Mol Med. 2019 Dec;11(12):e10581. doi: 10.15252/emmm.201910581. Epub 2019 Oct 21.

5.

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.

Low JL, Walsh RJ, Ang Y, Chan G, Soo RA.

Ther Adv Med Oncol. 2019 Aug 28;11:1758835919870360. doi: 10.1177/1758835919870360. eCollection 2019. Review.

6.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, Park SH, Schostak M, Gajate P, Cathomas R, Rajagopalan P, Grevel J, Bender S, Boix O, Nogai H, Ocker M, Ellinghaus P, Joerger M.

Lancet Oncol. 2019 Oct;20(10):1454-1466. doi: 10.1016/S1470-2045(19)30412-7. Epub 2019 Aug 9.

PMID:
31405822
7.

"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

Torlakovic E, Lim HJ, Adam J, Barnes P, Bigras G, Chan AWH, Cheung CC, Chung JH, Couture C, Fiset PO, Fujimoto D, Han G, Hirsch FR, Ilie M, Ionescu D, Li C, Munari E, Okuda K, Ratcliffe MJ, Rimm DL, Ross C, Røge R, Scheel AH, Soo RA, Swanson PE, Tretiakova M, To KF, Vainer GW, Wang H, Xu Z, Zielinski D, Tsao MS.

Mod Pathol. 2020 Jan;33(1):4-17. doi: 10.1038/s41379-019-0327-4. Epub 2019 Aug 5. Review.

8.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T.

Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.

9.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.

J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

PMID:
30892989
10.

Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).

Halmos B, Tan EH, Soo RA, Cadranel J, Lee MK, Foucher P, Hsia TC, Hochmair M, Griesinger F, Hida T, Kim E, Melosky B, Märten A, Carcereny E.

Lung Cancer. 2019 Jan;127:103-111. doi: 10.1016/j.lungcan.2018.10.028. Epub 2018 Nov 2.

11.

Somatic mutations and immune checkpoint biomarkers.

Parris BA, Shaw E, Pang B, Soong R, Fong K, Soo RA.

Respirology. 2019 Mar;24(3):215-226. doi: 10.1111/resp.13463. Epub 2019 Jan 12. Review.

12.

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS.

Wu YL, Planchard D, Lu S, Sun H, Yamamoto N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, Park K, Soo RA, Chang JWC, Alip A, Peters S, Douillard JY.

Ann Oncol. 2019 Feb 1;30(2):171-210. doi: 10.1093/annonc/mdy554.

13.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
14.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T.

Future Oncol. 2018 Nov;14(27):2861-2874. doi: 10.2217/fon-2018-0711. Epub 2018 Oct 19.

15.

Can We Prevent Resistance to Osimertinib? Combination or Sequential.

Kim MH, Lim SM, Lee K, Soo RA, Cho BC.

J Thorac Oncol. 2018 Jul;13(7):877-879. doi: 10.1016/j.jtho.2018.05.012. No abstract available.

16.

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis.

Soo RA, Chen Z, Yan Teng RS, Tan HL, Iacopetta B, Tai BC, Soong R.

Oncotarget. 2018 May 15;9(37):24801-24820. doi: 10.18632/oncotarget.24835. eCollection 2018 May 15.

17.

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies in non-small cell lung cancer.

Tsui DWY, Murtaza M, Wong ASC, Rueda OM, Smith CG, Chandrananda D, Soo RA, Lim HL, Goh BC, Caldas C, Forshew T, Gale D, Liu W, Morris J, Marass F, Eisen T, Chin TM, Rosenfeld N.

EMBO Mol Med. 2018 Jun;10(6). pii: e7945. doi: 10.15252/emmm.201707945.

18.

Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.

Limviphuvadh V, Tan CS, Konishi F, Jenjaroenpun P, Xiang JS, Kremenska Y, Mu YS, Syn N, Lee SC, Soo RA, Eisenhaber F, Maurer-Stroh S, Yong WP.

BMC Cancer. 2018 May 11;18(1):555. doi: 10.1186/s12885-018-4471-x.

19.

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC.

Cancer Res. 2018 Jun 15;78(12):3350-3362. doi: 10.1158/0008-5472.CAN-17-3146. Epub 2018 Apr 18.

20.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
21.

Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.

Lim SM, Syn NL, Cho BC, Soo RA.

Cancer Treat Rev. 2018 Apr;65:1-10. doi: 10.1016/j.ctrv.2018.02.006. Epub 2018 Feb 20. Review.

PMID:
29477930
22.

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

Soo RA, Yun Lim JS, Asuncion BR, Fazreen Z, Herrera MC, Mohd Omar MF, Diem Phuong NH, Seet JE, Amanuel B, Iacopetta B, Byrne D, Hendry S, Fox S, Soong R.

Oncotarget. 2018 Jan 2;9(6):6841-6851. doi: 10.18632/oncotarget.23827. eCollection 2018 Jan 23.

23.

Third generation EGFR TKIs: current data and future directions.

Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE, Choo JR, Goh BC, Soo RA.

Mol Cancer. 2018 Feb 19;17(1):29. doi: 10.1186/s12943-018-0778-0. Review.

24.

Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non-small cell lung cancer.

Ali A, Levantini E, Teo JT, Goggi J, Clohessy JG, Wu CS, Chen L, Yang H, Krishnan I, Kocher O, Zhang J, Soo RA, Bhakoo K, Chin TM, Tenen DG.

EMBO Mol Med. 2018 Mar;10(3). pii: e8313. doi: 10.15252/emmm.201708313.

25.

Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer.

Choo JR, Tan CS, Soo RA.

Target Oncol. 2018 Apr;13(2):141-156. doi: 10.1007/s11523-018-0554-5. Review.

PMID:
29423594
26.

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.

Soo RA, Lim SM, Syn NL, Teng R, Soong R, Mok TSK, Cho BC.

Lung Cancer. 2018 Jan;115:12-20. doi: 10.1016/j.lungcan.2017.11.009. Epub 2017 Nov 13. Review.

PMID:
29290252
27.

De-novo and acquired resistance to immune checkpoint targeting.

Syn NL, Teng MWL, Mok TSK, Soo RA.

Lancet Oncol. 2017 Dec;18(12):e731-e741. doi: 10.1016/S1470-2045(17)30607-1. Review.

PMID:
29208439
28.

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K.

Cancer Treat Rev. 2017 Dec;61:70-81. doi: 10.1016/j.ctrv.2017.10.003. Epub 2017 Oct 25. Review.

PMID:
29121501
29.

Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).

Nokihara H, Lu S, Mok TSK, Nakagawa K, Yamamoto N, Shi YK, Zhang L, Soo RA, Yang JC, Sugawara S, Nishio M, Takahashi T, Goto K, Chang J, Maemondo M, Ichinose Y, Cheng Y, Lim WT, Morita S, Tamura T.

Ann Oncol. 2017 Nov 1;28(11):2698-2706. doi: 10.1093/annonc/mdx419.

30.

Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study.

Heong V, Syn NL, Lee XW, Sapari NS, Koh XQ, Adam Isa ZF, Sy Lim J, Lim D, Pang B, Thian YL, Ng LK, Wong AL, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP.

Int J Cancer. 2018 May 1;142(9):1890-1900. doi: 10.1002/ijc.31091. Epub 2017 Oct 17.

31.

Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.

Lim SM, Chang H, Cha YJ, Liang S, Tai YC, Li G, Pestova E, Policht F, Perez T, Soo RA, Park WY, Kim HR, Shim HS, Cho BC.

Lung Cancer. 2017 Sep;111:79-83. doi: 10.1016/j.lungcan.2017.07.016. Epub 2017 Jul 12.

PMID:
28838404
32.

Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs?

Tan CS, Cho BC, Soo RA.

Lung Cancer. 2017 Jun;108:29-37. doi: 10.1016/j.lungcan.2017.02.012. Epub 2017 Feb 22. Review.

PMID:
28625644
33.

Scientific Advances in Thoracic Oncology 2016.

Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR.

J Thorac Oncol. 2017 Aug;12(8):1183-1209. doi: 10.1016/j.jtho.2017.05.019. Epub 2017 Jun 1. Review.

34.

The KEY to the end of chemotherapy in non-small cell lung cancer?

Huang Y, Soo RA.

Ann Transl Med. 2017 Apr;5(7):166. doi: 10.21037/atm.2017.03.55. No abstract available.

35.

A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT.

Oncotarget. 2017 Jun 20;8(25):41474-41486. doi: 10.18632/oncotarget.17102. Review.

36.

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.

Aw DC, Tan EH, Chin TM, Lim HL, Lee HY, Soo RA.

Asia Pac J Clin Oncol. 2018 Feb;14(1):23-31. doi: 10.1111/ajco.12687. Epub 2017 May 2. Review.

PMID:
28464435
37.

Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

Soo RA, Kubo A, Ando M, Kawaguchi T, Ahn MJ, Ou SI.

Clin Lung Cancer. 2017 Sep;18(5):535-542. doi: 10.1016/j.cllc.2017.01.005. Epub 2017 Jan 19.

PMID:
28433570
38.

Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.

Soo RA, Adjei AA.

J Thorac Oncol. 2017 Apr;12(4):602-606. doi: 10.1016/j.jtho.2017.01.025. No abstract available.

39.

Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer.

Soo RA, Kim HR, Asuncion BR, Fazreen Z, Omar MFM, Herrera MC, Yun Lim JS, Sia G, Soong R, Cho BC.

Lung Cancer. 2017 Mar;105:17-22. doi: 10.1016/j.lungcan.2017.01.008. Epub 2017 Jan 15.

PMID:
28236980
40.

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.

Kumarakulasinghe NB, Syn N, Soon YY, Asmat A, Zheng H, Loy EY, Pang B, Soo RA.

Oncotarget. 2016 Dec 20;7(51):85542-85550. doi: 10.18632/oncotarget.13458.

41.

Quantitative Accuracy and Lesion Detectability of Low-Dose 18F-FDG PET for Lung Cancer Screening.

Schaefferkoetter JD, Yan J, Sjöholm T, Townsend DW, Conti M, Tam JK, Soo RA, Tham I.

J Nucl Med. 2017 Mar;58(3):399-405. doi: 10.2967/jnumed.116.177592. Epub 2016 Sep 29.

42.

Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression.

Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E.

Sci Transl Med. 2016 Aug 3;8(350):350ra104. doi: 10.1126/scitranslmed.aad6066.

PMID:
27488898
43.

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.

Lim JS, Soo RA.

Ther Adv Respir Dis. 2016 Oct;10(5):444-54. doi: 10.1177/1753465816661091. Epub 2016 Jul 31. Review.

44.

Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.

Zhang WC, Chin TM, Yang H, Nga ME, Lunny DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, Lim PX, Lee JZ, Tan BJ, Shyh-Chang N, Lim EH, Lim WT, Tan DS, Tan EH, Tai BC, Soo RA, Tam WL, Lim B.

Nat Commun. 2016 Jun 21;7:11702. doi: 10.1038/ncomms11702.

45.

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.

Ang YL, Lim JS, Soo RA.

Onco Targets Ther. 2016 May 30;9:3187-95. doi: 10.2147/OTT.S84356. eCollection 2016. Review.

46.

Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.

Soo RA, Syn N, Lee SC, Wang L, Lim XY, Loh M, Tan SH, Zee YK, Wong AL, Chuah B, Chan D, Lim SE, Goh BC, Soong R, Yong WP.

Sci Rep. 2016 Jun 14;6:27826. doi: 10.1038/srep27826.

47.

Evaluation of Scoring Systems and Prognostic Factors in Patients With Spinal Metastases From Lung Cancer.

Tan JH, Tan KA, Zaw AS, Thomas AC, Hey HW, Soo RA, Kumar N.

Spine (Phila Pa 1976). 2016 Apr;41(7):638-44. doi: 10.1097/BRS.0000000000001279.

PMID:
27018903
48.

Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.

Tan CS, Cho BC, Soo RA.

Lung Cancer. 2016 Mar;93:59-68. doi: 10.1016/j.lungcan.2016.01.003. Epub 2016 Jan 8. Review.

PMID:
26898616
49.

Shedding light on the molecular determinants of response to anti-PD-1 therapy.

Soo RA.

Transl Lung Cancer Res. 2015 Dec;4(6):816-9. doi: 10.3978/j.issn.2218-6751.2015.05.06.

50.

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study.

Syn NL, Wang L, Wong AL, Soe MY, Chuah B, Chan D, Tan SH, Soo RA, Lee SC, Goh BC, Yong WP.

Cancer Sci. 2016 Feb;107(2):173-80. doi: 10.1111/cas.12856. Epub 2016 Feb 8.

Supplemental Content

Support Center